Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Tesamorelin Dosing Protocol: 5 mg Vial — Daily Dosing Schedule & Supplies

Tesamorelin FDA-approved GHRH analogue dosing guide for the 5 mg vial, based on the Egrifta SV 2 mg/day protocol for visceral fat reduction.

Go to peptide profileCalculate your dose

Quickstart highlights

Tesamorelin (TH9507) is a stabilized GHRH analogue where the native GHRH is conjugated to trans-3-hexenoic acid, improving stability against DPP-IV cleavage.

  • Concentration: 2 mg/mL (5 mg vial + 2.5 mL bacteriostatic water).
  • At 2 mg/mL: 1 mg = 50 units, 2 mg = 100 units (FDA-approved Egrifta SV daily dose).
  • Falutz et al. Phase 3: 2 mg/day reduced visceral adipose tissue by 15.2% at 26 weeks.
  • One 5 mg vial provides 2.5 days at 2 mg/day — approximately 3 vials per week needed.
  • Refrigerate; use within 28 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4100050Once daily1 mg — 50 units; starting half-dose to assess tolerability; one 5 mg vial provides 5 daily doses
5-262000100Once daily2 mg — 100 units (FDA-approved Egrifta SV dose); one 5 mg vial provides 2.5 daily doses — approximately 2 vials per week at 2 mg/day

Reconstitution steps

  1. Draw 2.5 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until lyophilized powder dissolves completely; do not shake.
  3. Final concentration: 2 mg/mL (5 mg / 2.5 mL). At 2 mg/mL: 2 mg = 100 units on a U-100 syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days. One 5 mg vial provides 2.5 days at 2 mg/day.

Supplies needed

4-week plan

  • 6 vials
  • 28 syringes
  • 15 mL bac water
  • 28 alcohol swabs

12-week plan

  • 20 vials
  • 84 syringes
  • 50 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Reduce visceral adipose tissue through the FDA-approved 2 mg/day tesamorelin GHRH analogue protocol, with the 5 mg vial covering 2.5 days of maintenance dosing at once-daily injection.

Cycle length: 26 weeks on.

Off-cycle: 8 weeks off; tesamorelin is typically used in long cycles (26 weeks per clinical trial protocols).

Storage & handling

Lyophilized: store in refrigerator at 2–8 °C (brand Egrifta SV is refrigerator-stable lyophilized). Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. Note: at 2 mg/day, you use one vial every 2.5 days — approximately 3 vials per week.

Injection & tracking tips

  • Inject subcutaneously in the abdomen (not into scar tissue or navel) once daily at the same time each day.
  • Tesamorelin is FDA-approved; the Egrifta SV formulation is 2 mg once daily for HIV-associated lipodystrophy. The same dose is used in off-label body composition protocols.
  • Rotate within a quadrant of the abdomen daily to minimize local reactions.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure waist circumference and visceral fat (via DEXA or CT if available) at baseline, 12 weeks, and 26 weeks.
  • Track IGF-1 every 8 weeks — tesamorelin raises IGF-1 significantly; target upper-normal range for age.
  • Monitor fasting glucose monthly — GH elevation from tesamorelin can impair insulin sensitivity.
Log your cycle in the calculator →

How this works & references

Tesamorelin (TH9507) is a stabilized GHRH analogue where the native GHRH is conjugated to trans-3-hexenoic acid, improving stability against DPP-IV cleavage. FDA-approved in 2010 as Egrifta and Egrifta SV (2019) for HIV-associated lipodystrophy (excess visceral fat). In Phase 3 trials (Falutz et al., 2010), 2 mg/day reduced visceral adipose tissue by 15.2% at 26 weeks versus 0.7% with placebo. Tesamorelin also improved triglycerides and lean body mass as secondary endpoints.

Sources

Frequently asked questions

What makes tesamorelin different from other GHRH analogues for fat loss?
Tesamorelin is the only GHRH analogue FDA-approved for a fat-reduction indication. Phase 3 data specifically documented 15.2% visceral fat reduction — a validated clinical endpoint that other GHRH analogues lack in equivalent RCT data. It also reduces triglycerides as a secondary benefit.
Can tesamorelin be used for general anti-aging or body composition (not HIV)?
Tesamorelin is only FDA-approved for HIV-associated lipodystrophy. Off-label use for visceral fat reduction and body composition in non-HIV patients is practiced in some clinics but lacks Phase 3 data for that population.
How many 5 mg vials do I need for a 26-week protocol?
At 2 mg/day, total consumption is 2 mg × 182 days = 364 mg. At 5 mg/vial: 364 ÷ 5 = 72.8 vials. Approximately 73 vials are needed for the full 26-week FDA-approved protocol — making the 10 mg or 20 mg vials far more economical.
Is tesamorelin WADA-prohibited?
Yes — GHRH analogues including tesamorelin are listed under WADA S2 (Peptide Hormones, Growth Factors) as GH secretagogues. Athletes subject to anti-doping testing should not use tesamorelin.
When should I see results for visceral fat reduction?
Significant visceral fat reduction becomes measurable at 12 weeks in the Phase 3 data. Maximum reduction occurred at 26 weeks (15.2% visceral fat loss). Waist circumference is a practical monitoring surrogate — expect 2–5 cm reduction over 26 weeks in responders.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →